Ovarian
TREVI
A Randomised, Open-Label, Phase 3 Study of AZD5335 vs. Mirvetuximab Soravtansine in FRα-High and AZD5335 vs. Investigator’s Choice Chemotherapy in FRα-Low Expressing High-Grade Platinum-Resistant Epithelial Ovarian Cancer Patients (TREVI)
Trial overview
Clinical Area
Medical Oncology
Disease
Ovarian
Disease site
Gynaecology
Study Phase
III
Trial Identifiers
Registration number: NCT07218809
Principal Investigator(s)
··
··